Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. FHLC: which is better?

Bottom line

XLV vs FHLC: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FHLC (Fidelity MSCI Health Care Index ETF) have nearly the same top holdings — their top 25 positions are about 98% the same by weight.

But FHLC is far broader, holding 337 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.

XLV is cheaper at 0.08% vs 0.084% — a difference of $0.40 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +7.2% for FHLC (reporting dates differ).

Updated Nov 19, 2026

XLV vs FHLC side by side

XLVFHLC
TypeETFETF
Fund familySPDR (State Street)Fidelity
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%0.084%
Annual cost per $10k$8$8.4
10-yr cost on $10k (prospectus)$103$108
Max front loadNoneNone
12b-1 fee0.02%0%
1-yr return+14.5%+2.6%
5-yr return (annualized)+8.1%+7.2%
10-yr return (annualized)+9.8%+8.8%
Best quarter+14.5%+16.4%
Worst quarter−12.7%−13.1%
Net assets (fund)$40.6B$3.3B
Number of holdings65337
Portfolio turnover2%3%
Returns as ofDec 31, 2025Nov 30, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVFHLCDifference
2024+2.5%+2.6%−0.1%
2023+2.0%+2.5%−0.5%
2022−2.1%−5.5%+3.4%
2021+25.9%+20.4%+5.5%
2020+13.3%+18.1%−4.9%
2019+20.7%+21.9%−1.3%
2018+6.3%+5.5%+0.8%
2017+21.7%+23.3%−1.6%
2016−2.8%−3.3%+0.5%

Source: Fund prospectus bar charts

Holdings overlap

25 of XLV's top 25 holdings also appear in FHLC's top 25.

Shared top holdings
HoldingXLVFHLC
Eli Lilly & Co16.51%13.35%
Johnson & Johnson10.64%8.93%
AbbVie Inc7.74%6.42%
UnitedHealth Group Inc6.57%5.44%
Merck & Co Inc5.52%4.66%
Amgen Inc3.40%3.00%
Thermo Fisher Scientific Inc3.24%3.09%
Abbott Laboratories2.75%2.66%
Gilead Sciences Inc2.73%2.34%
Intuitive Surgical Inc2.45%1.82%
Pfizer Inc2.39%2.06%
CVS Health Corp2.30%1.92%
Vertex Pharmaceuticals Inc2.19%1.76%
Danaher Corp2.09%1.80%
Bristol-Myers Squibb Co2.05%1.93%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

FHLC top 10

  1. Eli Lilly & Co — 13.35%
  2. Johnson & Johnson — 8.93%
  3. AbbVie Inc — 6.42%
  4. UnitedHealth Group Inc — 5.44%
  5. Merck & Co Inc — 4.66%
  6. Thermo Fisher Scientific Inc — 3.09%
  7. Amgen Inc — 3.00%
  8. Abbott Laboratories — 2.66%
  9. Gilead Sciences Inc — 2.34%
  10. Pfizer Inc — 2.06%

FAQ

What is the difference between XLV and FHLC?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FHLC (Fidelity MSCI Health Care Index ETF) have nearly the same top holdings — their top 25 positions are about 98% the same by weight. But FHLC is far broader, holding 337 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
Which is cheaper, XLV or FHLC?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and FHLC?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.